Cost- utility of the vaccine against the Human Papiloma Virus in peruvian women;Costo-Utilidad De La Vacuna Contra El Virus De Papiloma Humano En Mujeres Peruanas

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 28, Issue 3, 2011, Pages 416-425

  Gutiérrez Aguado, Alfonso ^a,b  

^a UNIVERSIDAD CÉSAR VALLEJO   (Peru)

^b INSTITUTO NACIONAL DE SALUD   (Peru)

Author keywords

Costs and cost analysis (source: MeSH NLM); Inmunization; Papillomavirus vaccines; Uterine cervical neoplasms

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER;

EID: 80055104603     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: 10.1590/S1726-46342011000300003     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
2. Velásquez A, Seclén Y, Poquioma E, Cachay C, Espinoza R. Munayco C. La carga de enfermedad y lesiones en el Perú: Ajustado con datos nacionales de morbilidad y mortalidad. Lima: MINSA/USAID; 2009.
3. World Health Organization. Institut Català d'Oncologia. Human Papillomavirus and Related Cancers in Peru. WHO/ ICO Information Centre on HPV and Cervical Cancer. Barcelona: WHO/ICO HPV Information Centre; 2010.
4. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85(12):958-64.
5. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1-10.
6. Santos C. Virus del papiloma humano y Cáncer del Cuello Uterino en el Perú. Rev Per Ginecol Obstet. 2007;53(2):98-100.
7. Castellsagué X, Bosch F. Vacunas frente al virus del papiloma humano, para la prevención del cáncer de cuello uterino. Rev Per Ginecol Obstet. 2007;53(2):101-9.
8. Ministerio de Salud del Perú. Norma Técnica de Salud que establece el esquema nacional de vacunación. RM N°070-2011/MINSA:NTS N° 080-MINSA/DGSP V.02. Lima: MINSA; 2011.
9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd Edition. Oxford: Oxford University Press; 2005.
10. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine. 2008;26(49):6258-65.
11. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88-100.
12. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358(9286):993-8.
13. Solidoro A, Olivares L, Castellano C, Barriga O, Galdos R, Cáceres E. Cáncer de cuello uterino en el Perú: Impacto económico del cáncer invasor. Diagnóstico. 2004;43(1):29-33.
14. Gutiérrez S. Cáncer: costos de tratamiento en Perú. Lima: Acción Internacional para la Salud, Oficina de Coordinación América Latina y el Caribe; 2009.
15. Ministerio de Salud del Perú. Metodología para la Estimación de Costos Estándar en los Establecimientos de Salud. RM N° 195-2009/MINSA: Documento Técnico. Lima: MINSA; 2009.
16. Instituto Nacional de Enfermedades Neoplásicas. Norma Técnico Oncológica para la Prevención, Detección y manejo de lesiones Pre-malignas del Cuello Uterino a nivel Nacional. RJ N°121-RJ-INEN-2008. Lima: INEN; 2008.
17. Instituto Nacional de Enfermedades Neoplásicas. Guía Clínica en base a la Guías del NCCN "Cáncer de Cuello Uterino". RJ N°011-2011-J/INEN. Lima: INEN; 2011.
18. Ortega-Sanchez IR, Lee GM, Jacobs RJ, Prosser LA, Molinari NA, Zhang X, et al; Working Group on Leading Economic Issues for New Vaccine for Adolescents. Projected cost-effectiveness of new vaccines for adolescents in the United States. Pediatrics. 2008;121 Suppl 1:S63-78.
19. Puig-Junoy J, Lopez-Valcarcel BG. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med. 2009;48(5):444-8.
20. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics. 2009;27(2):127-47.
21. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16(3):217-30.
22. Rogoza RM, Ferko N, Bentley J, Meijer CJ, Berkhof J, Wang KL, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26 Suppl 5:F46-58.
23. Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009;27(44):6196-202.
24. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol. 2009;112(2):370-6.
25. Colantonio L, Gómez JA, Demarteau N, Standaert B, Pichón-Rivière A, Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine. 2009;27(40):5519-29.
26. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009;9:401.
27. Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26 Suppl 5:F29-45.
28. Jumaan A, LaMontagne D, Winkler J, Levin C, Ramos I. Vacuna contra el VPH en el Perú: Resumen de la experiencia y evaluación del proyecto piloto de la vacuna contra el VPH en el Perú. Lima: PATH-MINSA; 2009.
29. Paz S, Lee F, Carcamo C, Holmes K, Garnett G, Garcia P. Who is getting Pap smears in urban Peru?. Int J Epidemiol. 2008;37(4):862-9.
30. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26 Suppl 11:L59-72.
31. Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer. 2007;121(4):796-802.
32. El Banco Mundial [Internet]. Washington, DC: El Banco Mundial; c2011 [citado el 15 de julio del 2011]. Disponible en: http://datos.bancomundial.org/pais/peru
33. o 632. Washington, DC: OPS; 2009.